Impaired function and delayed regeneration of dendritic cells in COVID-19

COVID-19 中树突状细胞功能受损和再生延迟

阅读:6
作者:Elena Winheim ,Linus Rinke ,Konstantin Lutz ,Anna Reischer ,Alexandra Leutbecher ,Lina Wolfram ,Lisa Rausch ,Jan Kranich ,Paul R Wratil ,Johanna E Huber ,Dirk Baumjohann ,Simon Rothenfusser ,Benjamin Schubert ,Anne Hilgendorff ,Johannes C Hellmuth ,Clemens Scherer ,Maximilian Muenchhoff ,Michael von Bergwelt-Baildon ,Konstantin Stark ,Tobias Straub ,Thomas Brocker ,Oliver T Keppler ,Marion Subklewe ,Anne B Krug

Abstract

Disease manifestations in COVID-19 range from mild to severe illness associated with a dysregulated innate immune response. Alterations in function and regeneration of dendritic cells (DCs) and monocytes may contribute to immunopathology and influence adaptive immune responses in COVID-19 patients. We analyzed circulating DC and monocyte subsets in 65 hospitalized COVID-19 patients with mild/moderate or severe disease from acute illness to recovery and in healthy controls. Persisting reduction of all DC subpopulations was accompanied by an expansion of proliferating Lineage-HLADR+ cells lacking DC markers. Increased frequency of CD163+ CD14+ cells within the recently discovered DC3 subpopulation in patients with more severe disease was associated with systemic inflammation, activated T follicular helper cells, and antibody-secreting cells. Persistent downregulation of CD86 and upregulation of programmed death-ligand 1 (PD-L1) in conventional DCs (cDC2 and DC3) and classical monocytes associated with a reduced capacity to stimulate naïve CD4+ T cells correlated with disease severity. Long-lasting depletion and functional impairment of DCs and monocytes may have consequences for susceptibility to secondary infections and therapy of COVID-19 patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。